Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly  Settings
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
IndexS&P 500 P/E70.48 EPS (ttm)1.46 Insider Own1.28% Shs Outstand195.15M Perf Week-1.19%
Market Cap20.08B Forward P/E31.56 EPS next Y3.26 Insider Trans-3.48% Shs Float192.68M Perf Month11.82%
Income291.63M PEG2.88 EPS next Q0.67 Inst Own97.30% Short Float2.25% Perf Quarter19.64%
Sales1.23B P/S16.35 EPS this Y40.43% Inst Trans0.22% Short Ratio2.44 Perf Half Y15.05%
Book/sh10.70 P/B9.62 EPS next Y11.64% ROA12.40% Target Price116.80 Perf Year18.64%
Cash/sh5.24 P/C19.63 EPS next 5Y24.47% ROE17.66% 52W Range81.82 - 119.54 Perf YTD9.77%
Dividend- P/FCF- EPS past 5Y70.11% ROI14.39% 52W High-13.92% Beta0.48
Dividend %- Quick Ratio4.90 Sales past 5Y73.55% Gross Margin89.15% 52W Low25.76% ATR3.19
Employees1373 Current Ratio5.24 Sales Q/Q38.49% Oper. Margin36.74% RSI (14)57.76 Volatility3.62% 3.25%
OptionableYes Debt/Eq0.07 EPS Q/Q76.95% Profit Margin23.74% Rel Volume0.55 Prev Close101.82
ShortableYes LT Debt/Eq0.05 EarningsApr 25 BMO Payout- Avg Volume1.78M Price102.90
Recom1.80 SMA204.90% SMA507.01% SMA2004.18% Volume977,654 Change1.06%
26-Apr-13Reiterated UBS Buy $120 → $123
24-Sep-12Reiterated Canaccord Genuity Buy $115 → $132
25-Apr-12Reiterated Canaccord Genuity Buy $95 → $100
25-Apr-12Reiterated Barclays Overweight $84 → $104
26-Mar-12Initiated Canaccord Genuity Buy $95
23-Feb-12Upgrade UBS Neutral → Buy $73 → $99
10-Feb-12Upgrade Robert W. Baird Neutral → Outperform $72 → $100
10-Feb-12Reiterated Barclays Capital Overweight $77 → $84
21-Oct-11Reiterated UBS Neutral $57 → $70
27-Sep-11Reiterated Oppenheimer Outperform $63 → $74
26-Sep-11Reiterated Collins Stewart Buy $65 → $77
23-Sep-11Reiterated Brean Murray Buy $60 → $84
21-Jul-11Reiterated Brean Murray Buy $57 → $60
08-Jul-11Reiterated UBS Neutral $55 → $53
25-Apr-11Downgrade Needham Buy → Hold
21-Apr-11Reiterated Brean Murray Buy $100 → $114
25-Mar-11Reiterated Oppenheimer Outperform $99 → $104
23-Feb-11Reiterated Collins Stewart Buy $99 → $105
11-Feb-11Reiterated UBS Neutral $85 → $93
11-Feb-11Reiterated Collins Stewart Buy $80 → $99
16-May-13 05:15PM  Bayer's Xofigo Cleared in the US Zacks
05:01PM  Alexion Pharmaceuticals Inc. (ALXN): Today's Featured Drugs Laggard at TheStreet
03:38PM  A Fundamental, Bottom-Up Approach to Investing in Health Care: Portfolio Manager Finny Kuruvilla Discusses His Strategies with The Wall Street Transcript Wall Street Transcript
10:04AM  Big 5 Sporting Director Sells More Than 56K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
15-May-13 01:03PM  3 Stocks Underperforming Today In The Drugs Industry at TheStreet
09:16AM  AptarGroup CEO Sells 35K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
14-May-13 06:10AM  [$$] Biotech Fund: Many Healthy Returns at Barrons.com
10-May-13 05:15PM  Today's 3 Best Stocks at Motley Fool +6.06%
04:39PM  Cramer: Biotech Makes a Comeback at TheStreet
02:36PM  Friday movers: Tesla, Barnes & Noble extend gains at MarketWatch
12:52PM  Biotech Makes a Comeback TheStreet
09:54AM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
09-May-13 05:00PM  Alexion Pharmaceuticals Inc. (ALXN): Today's Featured Health Care Winner at TheStreet
08-May-13 12:10PM  Orphan Drug Companies Might Not Find A Parent at Forbes
10:00AM  Alexion to Present at the BofA Merrill Lynch 2013 Healthcare Conference Business Wire
07-May-13 11:56AM  Forbes Earnings Preview: PDL BioPharma at Forbes
04-May-13 01:04PM  ALEXION PHARMACEUTICALS INC Financials EDGAR Online Financials
03-May-13 08:30AM  The Market's Got This Biotech All Wrong at Motley Fool
01-May-13 07:51AM  Raptor's FDA Approval Is New Test For Orphan Drug Pricing at TheStreet
30-Apr-13 04:36PM  A Look at Biotechnologys Hot Name & Its Lack of Value at Motley Fool
07:33AM  ALEXION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
29-Apr-13 04:38PM  A Look at Biotechnologys Hot Name & Its Lack of Value at Motley Fool
11:03AM  Raised Guidance And Resolved Manufacturing Issues Support Alexion Shares at Seeking Alpha
26-Apr-13 01:02PM  Hepatitis C Space an Opportunity with the Potential for an Upside Surprise, According to Expert Analyst David Ferreiro Wall Street Transcript
11:49AM  Mark A. Emalfarb, Founder, Chairman, President and CEO of Dyadic International (DYAI), Interviews with The Wall Street Transcript Wall Street Transcript
25-Apr-13 06:01PM  Wall Street gains on earnings, data, but S&P record a hurdle Reuters +10.75%
05:39PM  Biogen Earnings Strong, But Celgene Just So-So Investor's Business Daily
04:47PM  Wall Street rises on earnings, data, but record a hurdle Reuters
04:36PM  US STOCKS-Wall Street rises on earnings, data, but record a hurdle at Reuters
04:30PM  Alexion Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha
04:27PM  ALXN Makes Bullish Cross Above Critical Moving Average at TheStreet
04:20PM  Alexion Soars on Q1 Results at Motley Fool
04:08PM  Alexion Rises On Unusually High Volume (ALXN) at TheStreet
02:35PM  Why Alexion Shares Popped at Motley Fool
12:00PM  Earnings Beat at Alexion, Ups View Zacks
11:43AM  Alexion Pharmaceuticals Earnings: Heres Why Investors are Excited Now at Wall St. Cheat Sheet
10:57AM  Biogen, Alexion shares climb on earnings as biotech rally persists at MarketWatch
10:56AM  Alexion 1Q income rises as Soliris sales improve AP
10:02AM  Big-Cap Biotech Earnings Calm Investor Nerves (Update) at TheStreet
10:00AM  Alexion Pharmaceuticals Earnings Call scheduled for 10:00 am ET today CCBN
07:54AM  BRIEF-Alexion Pharmaceuticals shares up 3.1 percent in premarket trade following results at Reuters
07:46AM  Big-Cap Biotech Earnings Look to Calm Investor Nerves at TheStreet
07:07AM  Q1 2013 Alexion Pharmaceuticals Earnings Release - Before Market Open CCBN
06:36AM  InPlay: Alexion Pharma announces Stephen Squinto, co-founder of Alexion, is being promoted to the newly created position of Executive Vice President, Chief Global Operations Officer Briefing.com
06:30AM  Alexion Reports First Quarter 2013 Results Business Wire
06:29AM  Alexion announces leadership expansion at theflyonthewall.com
06:15AM  Alexion Broadens and Strengthens its Executive Leadership Team Business Wire
23-Apr-13 05:04PM  Alexion Pharmaceuticals Earnings Preview: Can This Streak Continue? at Wall St. Cheat Sheet
04:30PM  Indexes End Near Highs Ahead Of Earnings from Apple, Cree at Investor's Business Daily
01:54PM  Are These Billion-Dollar Biotechs Overvalued? at Motley Fool
11:31AM  Forbes Earnings Preview: Alexion Pharmaceuticals, Inc. at Forbes
04:43AM  Catalyst Deserves The Attention at Seeking Alpha
22-Apr-13 07:14PM  Today's 3 Worst Stocks at Motley Fool
05:01PM  Alexion Pharmaceuticals Inc. (ALXN): Today's Featured Drugs Laggard at TheStreet
01:30PM  Multi-billion Dollar Hedge Fund Bullish on These Stocks at Motley Fool
01:03PM  4 Stocks Pushing The Drugs Industry Downward at TheStreet
21-Apr-13 11:45AM  5 Must-Watch Earnings Reports in the Health-Care Sector This Week at Motley Fool
19-Apr-13 11:56AM  Orphan Drug Biotechs Do It Best at Motley Fool
10:51AM  Worth Repeating: Vertex Is the Next Gilead Sciences at TheStreet
10:00AM  Alexion Pharmaceuticals Inc. Stock Buy Recommendation Reiterated (ALXN) at TheStreet
08:33AM  Worth Repeating: Vertex Is The Next Gilead Sciences at TheStreet
08:33AM  Worth Repeating: Vertex Is the Next Gilead Sciences at TheStreet
18-Apr-13 04:30PM  Omeros' OMS721 Files for Orphan Drug Status Zacks
15-Apr-13 01:03PM  5 Stocks Pushing The Drugs Industry Downward at TheStreet
10:25AM  Insiders Buy Shares of Digital Generation and Goodrich Petroleum; Alexion Pharma's CEO Sells at Minyanville
08:30AM  Top Insider Trades: DGIT GDP ALXN SPB at TheStreet
11-Apr-13 06:30PM  Orphan Drugs Could Lose Their Government Subsidies at BusinessWeek
10:00AM  Alexion Pharmaceuticals to Report First Quarter 2013 Results on Thursday, April 25, 2013 Business Wire
10-Apr-13 04:19PM  Alexion Pharmaceuticals Becomes #42 Most Shorted Nasdaq 100 Component, Replacing KLA-Tencor at TheStreet
11:15AM  Jenner Said to Raise $100 Million for Health-Care Fund at Bloomberg
08:12AM  Morning Call Express: Money Rotates As Market Aims For Highs T3 Live
07-Apr-13 06:01PM  Orphan Drug Prices Under Siege in Austerity-Minded Europe at Bloomberg
07:13AM  How to Play the Immediate Uncertainty of this Promising Biotech Stock at Motley Fool
05-Apr-13 12:51PM  Alexion's Manufacturing Concerns To Abate And Commercial Expansion To Drive Shares Higher at Seeking Alpha
11:19AM  3 Surprising Investment Ideas Straight From Obamacare at Motley Fool
04-Apr-13 05:00PM  Alexion Pharmaceuticals Inc. (ALXN): Today's Favorite Health Care Gainer at TheStreet
09:18AM  Finish Line President Sells More Than 31K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
03-Apr-13 02:17PM  12 Shocking Truths About Obamacare at Motley Fool
02-Apr-13 12:57PM  Alexion Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for ALXN at Forbes
12:20PM  Stocks Maintain Early Lead; Drugmakers Alexion, Regeneron Climb at Investor's Business Daily
11:58AM  [video] Mad Money Uncovered: Biomarin and Alexion Orphan Drug Stalwarts at TheStreet
11:50AM  [video] Nasdaq Midday Update at CNBC
09:18AM  Jim Cramer: Buy Akamai, Alexion Pharma, and These 2 Stocks at Wall St. Cheat Sheet
08:36AM  Myths In The Pricing Of New Drugs at Forbes
06:00AM  Cramer's Top Stock Picks: HES ALXN BMRN NFLX ENB AWK at TheStreet
01-Apr-13 07:46PM  Cramer's 'Mad Money' Recap: Checking My List at TheStreet
06:15PM  Cramer: Small Drug Stocks with Promising Pipelines at CNBC
06:15PM  [video] Two Health Plays For Your Portfolio at CNBC
05:15PM  Today's 3 Best Stocks at Motley Fool
03:19PM  [video] eBay Upgraded to Buy at CNBC
01:03PM  4 Stocks Raising The Health Care Sector Higher at TheStreet
28-Mar-13 07:21PM  Today's 3 Worst Stocks at Motley Fool
01:14PM  Alexion gets FDA warning over bacteria contamination at plant at MarketWatch
11:06AM  Analysts: Alexion Offers a Buying Opportunity and 4 New Opinions Investors Must Read at Wall St. Cheat Sheet
08:27AM  Alexion receives FDA Warning Letter for Rhode Island facility at theflyonthewall.com
07:33AM  InPlay: Alexion Pharma received a Warning Letter from the U.S. Food and Drug Administration regarding compliance with current Good Manufacturing Practices at its Rhode Island manufacturing facility Briefing.com
27-Mar-13 11:41PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Other Events EDGAR Online
26-Mar-13 05:01PM  Alexion Pharmaceuticals Inc. (ALXN): Drugs' Featured Daily Laggard at TheStreet
22-Mar-13 08:40AM  Alexion gets positive CHMP opinion on extended indication for eculizumab at theflyonthewall.com
19-Mar-13 07:12PM  1 Biotech Goes All In at Motley Fool
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company offers Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trails for its usage for the treatment of PNH pediatric trial, cold agglutinin disease, MPGN II/C3 nephropathy, hemolytic uremic syndrome, presensitized renal transplant, delayed kidney transplant graft function, ABO incompatible renal transplant, neuromyelitis optica, and myasthenia gravis. In addition, the company develops Asfotase alfa that is under Phase II clinical trail for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; and ALXN 1007, a novel humanized antibody for treating inflammatory disorders. Further, the company conducts preclinical trails on cPMP for treating metabolic disorders. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BELL LEONARDCEOMay 14Sale105.7431,1133,289,7591,361,212May 15 05:23 PM
BELL LEONARDCEOMay 13Sale104.946,220652,7271,392,325May 14 05:08 PM
BELL LEONARDCEOMay 10Sale100.1235,0003,504,2001,398,545May 14 05:08 PM
SQUINTO STEPHEN PEVP, Global Ops. OfficerApr 29Option Exercise33.7336,4991,231,027144,961May 01 06:29 PM
SQUINTO STEPHEN PEVP, Global Ops. OfficerApr 29Sale98.9636,4993,612,051108,462May 01 06:29 PM
MATHIS LARRYDirectorApr 29Sale99.033,115308,47829,456May 01 06:29 PM
Veneman Ann MDirectorApr 29Sale99.003,115308,3855,918May 01 06:29 PM
Islam SaqibSVP, Chief Strat & Port. Off.Apr 24Option Exercise0.0025,000025,000Apr 26 04:29 PM
BELL LEONARDCEOApr 17Sale95.0435,0003,326,4001,433,545Apr 19 04:25 PM
BELL LEONARDCEOApr 10Sale100.2426,7002,676,4081,468,545Apr 12 04:09 PM
BELL LEONARDCEOApr 02Sale99.978,300829,7511,495,245Apr 03 04:45 PM
BELL LEONARDCEOApr 01Sale95.0035,0003,325,0001,503,545Apr 03 04:45 PM
SQUINTO STEPHEN PEVP, Head of R&DMar 08Option Exercise19.5220,000390,350128,462Mar 12 04:39 PM
PARVEN ALVIN SDirectorMar 08Sale92.003,115286,5807,311Mar 12 04:39 PM
SQUINTO STEPHEN PEVP, Head of R&DMar 08Sale91.3620,0001,827,162108,462Mar 12 04:39 PM
BELL LEONARDCEOFeb 04Sale96.2711,8801,143,7181,522,045Feb 06 06:08 PM
SQUINTO STEPHEN PEVP, Head of R&DFeb 04Sale95.682,572246,08181,925Feb 06 06:07 PM
Hallal DavidEVP, Chief Commercial OfficerFeb 04Sale96.182,085200,53769,246Feb 06 06:07 PM
Sinha VikasEVP & CFOFeb 04Sale95.813,483333,692308,155Feb 06 06:08 PM
Hallal DavidEVP. Global Commercial OpsJan 29Sale94.3251248,29271,331Jan 30 05:07 PM
Sinha VikasEVP & CFOJan 29Sale94.3297591,962311,638Jan 30 05:12 PM
BELL LEONARDCEOJan 29Sale94.322,682252,9661,533,925Jan 30 05:21 PM
SQUINTO STEPHEN PEVP, Head of R&DJan 29Sale94.3276772,34384,497Jan 30 05:23 PM
SQUINTO STEPHEN PEVP, Head of R&DJan 28Sale94.5071567,56885,264Jan 30 05:23 PM
BELL LEONARDCEOJan 28Sale94.502,560241,9201,536,607Jan 30 05:21 PM
Sinha VikasEVP & CFOJan 28Sale94.501,00795,162312,613Jan 30 05:12 PM
Hallal DavidEVP. Global Commercial OpsJan 28Sale94.5063259,72471,843Jan 30 05:07 PM
BELL LEONARDCEOJan 15Sale98.5835,0003,450,4051,539,167Jan 17 05:02 PM
BELL LEONARDCEOJan 09Sale99.9627,1972,718,6121,574,167Jan 11 04:31 PM
BELL LEONARDCEOJan 02Sale99.937,803779,7541,601,364Jan 04 04:25 PM
BELL LEONARDCEODec 18Sale95.6835,0003,348,8001,609,167Dec 20 04:59 PM
Veneman Ann MDirectorDec 12Sale95.004,579435,0056,562Dec 14 04:53 PM
Moriarty John BSVP & General CounselDec 10Option Exercise0.0015,000015,000Dec 18 05:15 PM
NORBY R DOUGLASDirectorDec 10Option Exercise6.8122,000149,83060,673Dec 12 06:19 PM
NORBY R DOUGLASDirectorDec 10Sale93.0022,0002,046,00038,673Dec 12 06:19 PM
BELL LEONARDCEONov 28Option Exercise4.0313,51554,4651,692,682Nov 30 04:38 PM
BELL LEONARDCEONov 28Sale94.9748,5154,607,3341,644,167Nov 30 04:38 PM
PARVEN ALVIN SDirectorNov 19Option Exercise10.8430,000325,20037,311Nov 21 02:48 PM
PARVEN ALVIN SDirectorNov 19Sale91.3030,0002,739,0537,311Nov 21 02:48 PM
BELL LEONARDCEOOct 31Option Exercise4.035,31521,4191,687,149Nov 02 04:09 PM
Coissac PatriceSVP & Pres. ALXN Pharma Int'lOct 31Sale91.1684,7647,726,8881,118Nov 02 04:30 PM
BELL LEONARDCEOOct 31Sale94.997,982758,2371,679,167Nov 02 04:09 PM
Hallal DavidSVP. Global Commercial OpsOct 24Option Exercise8.1610,50085,68072,475Oct 26 04:06 PM
BELL LEONARDCEOOct 01Option Exercise4.0318,07072,8221,699,904Oct 03 04:28 PM
BELL LEONARDCEOOct 01Sale115.2718,0702,082,9461,681,834Oct 03 04:28 PM
BELL LEONARDCEOSep 28Option Exercise6.11125,384766,3051,748,214Sep 28 05:43 PM
BELL LEONARDCEOSep 28Sale111.4476,1008,480,5841,672,114Sep 28 05:43 PM
BELL LEONARDCEOSep 27Sale112.5767,0007,542,0111,632,550Sep 28 05:43 PM
Coissac PatriceSVP & Pres. ALXN Pharma Int'lAug 28Option Exercise42.6621,551919,366107,433Aug 29 04:42 PM
Coissac PatriceSVP & Pres. ALXN Pharma Int'lAug 28Sale106.3721,5512,292,38085,882Aug 29 04:42 PM
Coissac PatriceSVP & Pres. ALXN Pharma Int'lAug 27Option Exercise28.6541,9321,201,275127,814Aug 29 04:42 PM
Coissac PatriceSVP & Pres. ALXN Pharma Int'lAug 27Sale107.0541,9324,488,82185,882Aug 29 04:42 PM
LINK MAXDirectorAug 24Option Exercise14.4380,0001,154,000169,781Aug 28 04:12 PM
DUBIN THOMAS I HSVP & Chief Legal OfficerAug 23Sale103.3033,5283,463,57865,705Aug 27 04:15 PM
LINK MAXDirectorAug 14Sale103.8999,67310,355,24589,781Aug 15 07:39 PM
MADRI JOSEPH ADirectorAug 03Option Exercise4.2630,000127,800276,746Aug 07 04:24 PM
MADRI JOSEPH ADirectorAug 03Sale107.3230,0003,219,600246,746Aug 07 04:24 PM
Hallal DavidSVP. Global Commercial OpsJul 31Sale104.9968071,39361,975Jul 31 03:17 PM
SQUINTO STEPHEN PEVP, Research & DevelopmentJul 31Sale105.011,015106,58585,979Jul 31 04:44 PM
BELL LEONARDCEOJul 31Sale104.962,470259,2511,673,082Jul 31 05:46 PM
Sinha VikasSVP & CFOJul 31Sale104.9490094,446313,620Jul 31 03:38 PM
BELL LEONARDCEOJul 27Option Exercise5.2162,000323,0401,943,912Jul 31 05:46 PM
SQUINTO STEPHEN PEVP, Research & DevelopmentJul 27Option Exercise20.96100,0002,096,280187,662Jul 31 04:44 PM
Hallal DavidSVP. Global Commercial OpsJul 27Option Exercise17.6550,000882,500113,210Jul 31 03:17 PM
Sinha VikasSVP & CFOJul 27Option Exercise11.9230,000357,600345,388Jul 31 03:38 PM
Sinha VikasSVP & CFOJul 27Sale108.8930,8683,361,363314,520Jul 31 03:38 PM
Hallal DavidSVP. Global Commercial OpsJul 27Sale107.7250,5555,445,90862,655Jul 31 03:17 PM
Rummelt AndreasDirectorJul 27Sale107.0010,0001,070,00010,315Jul 31 02:43 PM
BELL LEONARDCEOJul 27Sale107.6062,0006,671,0801,881,912Jul 31 05:46 PM
SQUINTO STEPHEN PEVP, Research & DevelopmentJul 27Sale107.28100,66810,800,14986,994Jul 31 04:44 PM
SQUINTO STEPHEN PEVP, Research & DevelopmentJul 09Option Exercise17.9850,000899,000137,662Jul 11 04:26 PM
BELL LEONARDCEOJul 09Option Exercise3.54108,000382,2101,989,912Jul 10 05:08 PM
SQUINTO STEPHEN PEVP, Research & DevelopmentJul 09Sale100.4450,0005,021,77287,662Jul 11 04:26 PM
BELL LEONARDCEOJul 09Sale100.40108,00010,843,2041,881,912Jul 10 05:08 PM
DUBIN THOMAS I HSVP & Chief Legal OfficerJun 15Option Exercise17.7042,578753,672143,159Jun 19 04:14 PM
Hallal DavidSVP, Global Commercial OpsJun 15Option Exercise11.9214,308170,55177,518Jun 19 04:27 PM
Hallal DavidSVP, Global Commercial OpsJun 15Sale93.6714,3081,340,23063,210Jun 19 04:27 PM
DUBIN THOMAS I HSVP & Chief Legal OfficerJun 15Sale93.9842,5784,001,350100,581Jun 19 04:14 PM
Rummelt AndreasDirectorJun 07Sale91.2910,000912,90020,315Jun 08 04:05 PM
SQUINTO STEPHEN PEVP, Research & DevelopmentJun 06Option Exercise17.6550,000882,500137,662Jun 08 03:34 PM
SQUINTO STEPHEN PEVP, Research & DevelopmentJun 06Sale90.0050,0004,500,00087,662Jun 08 03:34 PM
DUBIN THOMAS I HSVP and Chief Legal OfficerMay 29Option Exercise13.76103,4001,422,879203,981May 31 05:25 PM
MATHIS LARRYDirectorMay 29Option Exercise6.7433,000222,57044,115May 31 05:44 PM
MATHIS LARRYDirectorMay 29Sale92.0633,0003,038,14211,115May 31 05:44 PM
DUBIN THOMAS I HSVP and Chief Legal OfficerMay 29Sale92.02103,4009,514,485100,581May 31 05:25 PM
open in yahoo | open in reuters | open in google